29-Oct-2026 18:27:34

SANOFI INDIA Q3 : STANDALONE NET PROFIT UP 53.6% AT RS 116.7 CR (YOY), UP 39.8% (QOQ)

• Revenue up 3.4% at Rs 491.7 Cr (YOY), up 12.3% (QOQ); total net sales growth 4% (YOY). • PBT before exceptional items up 22% at Rs 157.7 Cr (YOY); PBT margin 34% vs 29% (YOY). • Diabetes insulin portfolio up 9% (YOY), holds 55% share of diabetes injectable segment; public sector business up 85%. • Employee plus other expenses down 8% (YOY); interim dividend of ₹75/share declared, record date 5 Nov 2026. • Caution: Q3 2025 base included exceptional personnel separation cost of ₹27.3 Cr. Impact: Interim dividend of ₹75/share and improved PBT margin; YoY profit growth aided by exceptional cost in base quarter.

Sanofi India Ltd

← Back to feed